99% Purity CAS 763113 -22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib

Model NO.
Dsung-Olaparib
Shelf Life
2 Years
CAS No.
763113-22-0
Test Method
HPLC
Specific
COA
Density
1.43
Refractive Index
1.702
MW
434.46300
Mf
C24h23fn4o3
Grade
Pharmaceutical Grade
Color
White or off-White Color
Application
Pharmaceutical Intermediate
Assay
HPLC 99%
Name
Olaparib Powder
Appearance
White or off-White Crystalline Powder
Product Name
Olaparib
Transport Package
Negotiable
Specification
99%
Trademark
D-Sung
Origin
Shaanxi
Production Capacity
1 Ton/Month
Reference Price
$ 18.00 - 27.00
Contact Us

Product Description

99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib
99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib
Product Description
99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib

 

Product Details

99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib

Product NameOlaparib
AppearanceWhite or off-white crystalline powder
CAS No.763113-22-0
MFC24H23FN4O3
MW434.46300
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair.Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy.
Application & Function

99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate OlaparibFunction
Olaparib as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2023, FDA expanded the approved use of Olaparib to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal receptor 2 (HER2)-negative metastatic breast cancer.
Applications:
Olaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism.It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.

Specification

99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib99% Purity CAS 763113-22-0 Olaparib Antineoplastic Olaparib Powder Pharmaceutical Intermediate Olaparib

 

 

Pharmaceutical Intermediate

PNEUTEC.IT, 2023